Phase 3 Readout~month
Phase 3 Topline: A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to De
- Company
- Novartis AG (NVS)
- Indication
- Hidradenitis Suppurativa
Other upcoming events for NVS
Phase 1 StartPhase 1 Start: A Phase 1b, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Study to Evaluate
Phase 2 StartPhase 2 Start: NeoPSMA: A Phase I/II, Open-label, Multi-center Study of Neoadjuvant Treatment With [177Lu]Lu-PSMA-R
Phase 2 StartPhase 2 Start: A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Ch
Phase 2 StartPhase 2 Start: An Open-label, Multi-center, Phase I/II Study of ERW316 as a Single Agent or in Combination With End
Phase 3 ReadoutPhase 3 Topline: A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.